Literature DB >> 22778214

TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway.

Julieta Díaz-Delfín1, Elayne Hondares, Roser Iglesias, Marta Giralt, Carme Caelles, Francesc Villarroya.   

Abstract

Fibroblast growth factor 21 (FGF21) is a member of the FGF family that reduces glycemia and ameliorates insulin resistance. Adipose tissue is a main target of FGF21 action. Obesity is associated with a chronic proinflammatory state. Here, we analyzed the role of proinflammatory signals in the FGF21 pathway in adipocytes, evaluating the effects of TNF-α on β-Klotho and FGF receptor-1 expression and FGF21 action in adipocytes. We also determined the effects of rosiglitazone on β-Klotho and FGF receptor-1 expression in models of proinflammatory signal induction in vitro and in vivo (high-fat diet-induced obesity). Because c-Jun NH(2)-terminal kinase 1 (JNK1) serves as a sensing juncture for inflammatory status, we also evaluated the involvement of JNK1 in the FGF21 pathway. TNF-α repressed β-Klotho expression and impaired FGF21 action in adipocytes. Rosiglitazone prevented the reduction in β-Klotho expression elicited by TNF-α. Moreover, β-Klotho levels were reduced in adipose tissue from high-fat diet-induced obese mice, whereas rosiglitazone restored β-Klotho to near-normal levels. β-Klotho expression was increased in white fat from JNK1(-/-) mice. The absence of JNK1 increased the responsiveness of mouse embryonic fibroblast-derived adipocytes and brown adipocytes to FGF21. In conclusion, we show that proinflammatory signaling impairs β-Klotho expression and FGF21 responsiveness in adipocytes. We also show that JNK1 activity is involved in modulating FGF21 effects in adipocytes. The impairment in the FGF21 response machinery in adipocytes and the reduction in FGF21 action in response to proinflammatory signals may play important roles in metabolic alterations in obesity and other diseases associated with enhanced inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778214     DOI: 10.1210/en.2012-1193

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  67 in total

1.  β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.

Authors:  Emmanuel Somm; Hugues Henry; Stephen J Bruce; Sébastien Aeby; Marta Rosikiewicz; Gerasimos P Sykiotis; Mohammed Asrih; François R Jornayvaz; Pierre Damien Denechaud; Urs Albrecht; Moosa Mohammadi; Andrew Dwyer; James S Acierno; Kristina Schoonjans; Lluis Fajas; Gilbert Greub; Nelly Pitteloud
Journal:  JCI Insight       Date:  2017-04-20

Review 2.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

3.  Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles.

Authors:  Ja Young Jeon; Sung-E Choi; Eun Suk Ha; Tae Ho Kim; Jong Gab Jung; Seung Jin Han; Hae Jin Kim; Dae Jung Kim; Yup Kang; Kwan-Woo Lee
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

Review 4.  Non-sympathetic control of brown adipose tissue.

Authors:  R Cereijo; J Villarroya; F Villarroya
Journal:  Int J Obes Suppl       Date:  2015-08-04

Review 5.  The role of innate immunity in the regulation of brown and beige adipogenesis.

Authors:  Vasileia Ismini Alexaki; Triantafyllos Chavakis
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

6.  Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and β-klotho expression decrease with fasting in northern elephant seals.

Authors:  Miwa Suzuki; Andrew Y Lee; José Pablo Vázquez-Medina; Jose A Viscarra; Daniel E Crocker; Rudy M Ortiz
Journal:  Gen Comp Endocrinol       Date:  2015-04-07       Impact factor: 2.822

7.  Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice.

Authors:  Nicholas Douris; Darko M Stevanovic; Ffolliott M Fisher; Theodore I Cisu; Melissa J Chee; Ngoc L Nguyen; Eleen Zarebidaki; Andrew C Adams; Alexei Kharitonenkov; Jeffrey S Flier; Timothy J Bartness; Eleftheria Maratos-Flier
Journal:  Endocrinology       Date:  2015-04-29       Impact factor: 4.736

8.  MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function.

Authors:  Ting Fu; Sunmi Seok; Sunge Choi; Zhang Huang; Kelly Suino-Powell; H Eric Xu; Byron Kemper; Jongsook Kim Kemper
Journal:  Mol Cell Biol       Date:  2014-09-02       Impact factor: 4.272

9.  Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.

Authors:  J M Gallego-Escuredo; J Gómez-Ambrosi; V Catalan; P Domingo; M Giralt; G Frühbeck; F Villarroya
Journal:  Int J Obes (Lond)       Date:  2014-05-12       Impact factor: 5.095

10.  The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Diana Moldovan; Alina Potra; Dacian Tirinescu; Cristian Budurea; Remus Orasan; Ioan Mihai Patiu; Cosmina Ioana Bondor; Dan Vladutiu; Mirela Gherman Caprioara
Journal:  Int Urol Nephrol       Date:  2016-12-10       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.